• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补肾壮骨片联合常规方案对绝经后骨质疏松症患者骨密度改善、功能恢复及骨折风险预防的作用研究。

Study on the Effect of Bushen Zhuanggu Tablet Combined with Conventional Regimen on Bone Mineral Density Improvement, Functional Recovery and Fracture Risk Prevention in Patients with Postmenopausal Osteoporosis.

机构信息

The Second Clinical Medical College of Guangzhou University of Chinese Medicine, China.

Department of Orthopedics, Gaozhou Hospital of Traditional Chinese Medicine, China.

出版信息

Comput Math Methods Med. 2023 Jul 7;2023:4846392. doi: 10.1155/2023/4846392. eCollection 2023.

DOI:10.1155/2023/4846392
PMID:37455682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10348851/
Abstract

OBJECTIVE

This case-control study was to explore the effect of Bushen Zhuanggu tablet combined with routine regimen on bone mineral density (BMD) improvement, functional recovery, and fracture prevention in postmenopausal osteoporosis (PMOP) patients.

METHODS

180 postmenopausal osteoporosis patients were randomly selected from communities A, B, and C cohorts as research subjects from January to May 2021. The study subjects were divided into three groups. The groups were in a 1 : 1 ratio according to the principles of nonrandomised, concurrent controlled trials, and methods. There were 60 participants in each group (group A, group B, and group C). Group A was treated with Bushen Zhuanggu tablet for antiosteoporosis + basic treatment (calcium supplement and vitamin D). Group C was given Bushen Zhuanggu tablet for antiosteoporosis intervention. Group B was given basic treatment (calcium supplement and vitamin D supplementation) as a control group. The follow-up time was 6 months after treatment. Finally, we compare the differences in calcium and phosphorus metabolism indexes, BMD, bone metabolism indexes, upper and lower limb muscle strength, and quality of life scores.

RESULTS

Group A, B, and C's effective rate was 98.33%, 80.00%, and 93.33%, respectively. The group A's effective rate was significantly higher than that in group B and C, and the difference was statistically significant ( < 0.05). After 6 months intervention, the levels of serum Ca, serum phosphorus (P), serum creatinine (Cr), and parathyroid hormone (PTH) in 3 groups decreased. Ca, P, Scr, and PTH levels in group A were the lowest among study groups, and the difference was statistically significant ( < 0.05). The increase in the BMD of lumbar spine, the left femoral neck, and Ward's triangle area of the three groups were observed with the highest data in group A. After 6 months of treatment, the levels of serum N-terminal propeptide of type I procollagen, PINP, and serum osteocalcin (OC) increased, while the levels of -cross-linked C-terminal telopeptide of type I collagen (-CTX) and alkaline phosphatase (ALP) decreased in the three groups. The improvement of all bone metabolic indexes in group A was significantly better than that in B and C groups, and the difference was statistically significant ( < 0.05). The enhanced upper limb muscle strength and the shorter standing-walking timing test (TUGT) time were observed after 6 months of treatment. The improvement effect of upper and lower limb muscle strength in group A was significantly better than that in B and C groups, and the difference was statistically significant ( < 0.05). There were significant differences in physiological function, life function, general health status, physical pain, mental state, emotional function, vitality, and social function among the three groups after 6 months treatment, and the difference was statistically significant ( < 0.05). The score of quality of life in group A was higher than that in B and C groups, and the difference was statistically significant ( < 0.05).

CONCLUSION

Bushen Zhuanggu tablet combined with conventional therapy is effective in the postmenopausal osteoporosis treatment, which effectively increase the BMD, regulate calcium and phosphorus metabolism, promote the recovery of limb function, prevent the recurrence of fracture, and improve the patients' quality of life. This treatment scheme is worth popularizing.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/682d/10348851/c874f87f2f54/CMMM2023-4846392.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/682d/10348851/560de506e909/CMMM2023-4846392.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/682d/10348851/c874f87f2f54/CMMM2023-4846392.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/682d/10348851/560de506e909/CMMM2023-4846392.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/682d/10348851/c874f87f2f54/CMMM2023-4846392.002.jpg
摘要

目的

本病例对照研究旨在探讨补肾壮骨片联合常规方案对绝经后骨质疏松症(PMOP)患者骨密度(BMD)改善、功能恢复和骨折预防的影响。

方法

2021 年 1 月至 5 月,从社区 A、B、C 队列中随机抽取 180 例绝经后骨质疏松症患者作为研究对象。研究对象按非随机同期对照试验原则和方法分为三组,每组按 1:1 比例分组,共 60 例(组 A、组 B、组 C)。组 A 给予补肾壮骨片抗骨质疏松+基础治疗(补钙和维生素 D)。组 C 给予补肾壮骨片抗骨质疏松干预。组 B 给予基础治疗(补钙和维生素 D 补充)作为对照组。治疗后随访 6 个月。最后,比较各组钙磷代谢指标、BMD、骨代谢指标、上下肢肌肉力量和生活质量评分的差异。

结果

组 A、B、C 的有效率分别为 98.33%、80.00%和 93.33%。组 A 的有效率明显高于组 B 和 C,差异有统计学意义(<0.05)。干预 6 个月后,3 组血清 Ca、血清磷(P)、血清肌酐(Cr)和甲状旁腺激素(PTH)水平降低。组 A 血清 Ca、P、Scr 和 PTH 水平最低,差异有统计学意义(<0.05)。三组腰椎、左侧股骨颈和 Ward 三角区 BMD 均有升高,组 A 数据最高。治疗 6 个月后,3 组血清Ⅰ型前胶原 N 端肽、PINP 和血清骨钙素(OC)水平升高,而血清Ⅰ型胶原交联 C 端肽(CTX)和碱性磷酸酶(ALP)水平降低。组 A 各项骨代谢指标改善均明显优于 B、C 组,差异有统计学意义(<0.05)。治疗 6 个月后,上肢肌肉力量增强,站立行走计时测试(TUGT)时间缩短。组 A 上下肢肌肉力量改善效果明显优于 B、C 组,差异有统计学意义(<0.05)。治疗 6 个月后,三组生理功能、生活功能、一般健康状况、躯体疼痛、精神状态、情绪功能、活力和社会功能均有显著差异,差异有统计学意义(<0.05)。组 A 生活质量评分高于 B、C 组,差异有统计学意义(<0.05)。

结论

补肾壮骨片联合常规疗法治疗绝经后骨质疏松症有效,能有效提高 BMD,调节钙磷代谢,促进肢体功能恢复,预防骨折复发,提高患者生活质量。该治疗方案值得推广。

相似文献

1
Study on the Effect of Bushen Zhuanggu Tablet Combined with Conventional Regimen on Bone Mineral Density Improvement, Functional Recovery and Fracture Risk Prevention in Patients with Postmenopausal Osteoporosis.补肾壮骨片联合常规方案对绝经后骨质疏松症患者骨密度改善、功能恢复及骨折风险预防的作用研究。
Comput Math Methods Med. 2023 Jul 7;2023:4846392. doi: 10.1155/2023/4846392. eCollection 2023.
2
Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.重组人甲状旁腺激素(1-34)在治疗绝经后骨质疏松症方面的疗效和安全性与阿仑膦酸钠相似。
Medicine (Baltimore). 2018 Nov;97(47):e13341. doi: 10.1097/MD.0000000000013341.
3
Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.间歇性鼻内给予200 IU鲑鱼降钙素和低剂量1α(OH)维生素D3对绝经后骨质疏松症女性腰椎和髋部骨密度及生化骨标志物的影响:一项初步研究。
Clin Rheumatol. 2005 Jun;24(3):232-8. doi: 10.1007/s10067-004-1004-6. Epub 2005 Jan 13.
4
Bone Turnover Markers and Bone Mineral Density to Predict Osteoporotic Fractures in Older Women: A Retrospective Comparative Study.骨转换标志物和骨密度预测老年女性骨质疏松性骨折:一项回顾性比较研究。
Orthop Surg. 2020 Feb;12(1):116-123. doi: 10.1111/os.12596. Epub 2019 Dec 27.
5
Effectiveness and safety of vitamin D in relation to bone health.维生素D对骨骼健康的有效性与安全性。
Evid Rep Technol Assess (Full Rep). 2007 Aug(158):1-235.
6
Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial.多菌种益生菌补充剂对骨质疏松绝经后妇女骨骼健康的影响:一项随机、双盲、对照试验。
J Am Coll Nutr. 2017 Sep-Oct;36(7):497-506. doi: 10.1080/07315724.2017.1318724. Epub 2017 Jun 19.
7
Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.巴勒斯坦绝经后骨质疏松症女性和正常女性的血清25-羟基维生素D及骨转换标志物
Arch Osteoporos. 2017 Dec;12(1):13. doi: 10.1007/s11657-017-0306-7. Epub 2017 Jan 26.
8
Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.盐酸雷洛昔芬对科威特骨质疏松症绝经后妇女骨密度和骨转换的影响。
Arch Osteoporos. 2014;9:189. doi: 10.1007/s11657-014-0189-9. Epub 2014 Jul 19.
9
Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.鲑鱼降钙素预防维持性透析患者骨质疏松症的研究
Chin Med J (Engl). 2008 Jul 20;121(14):1280-4.
10
Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.特立帕肽与阿仑膦酸钠治疗骨质疏松症:骨转换生化标志物、骨密度和生活质量的变化。
Med Sci Monit. 2011 Aug;17(8):CR442-448. doi: 10.12659/msm.881905.

引用本文的文献

1
Efficacy of Chinese herbal medicine in patients with osteoporosis: a systematic review and meta-analysis.中药治疗骨质疏松症患者的疗效:一项系统评价与荟萃分析
Front Med (Lausanne). 2025 Jul 25;12:1620264. doi: 10.3389/fmed.2025.1620264. eCollection 2025.
2
The therapeutic mechanism of Compound Lurong Jiangu Capsule for the treatment of cadmium-induced osteoporosis: network pharmacology and experimental verification.复方鹿蓉健骨胶囊治疗镉致骨质疏松症的作用机制:网络药理学与实验验证。
Front Endocrinol (Lausanne). 2024 Jul 10;15:1331488. doi: 10.3389/fendo.2024.1331488. eCollection 2024.
3
Retracted: Study on the Effect of Bushen Zhuanggu Tablet Combined with Conventional Regimen on Bone Mineral Density Improvement, Functional Recovery and Fracture Risk Prevention in Patients with Postmenopausal Osteoporosis.

本文引用的文献

1
Effect of exercise on bone mineral density among patients with osteoporosis and osteopenia: A systematic review and network meta-analysis.运动对骨质疏松症和骨量减少症患者骨密度的影响:系统评价和网络荟萃分析。
J Clin Nurs. 2022 Aug;31(15-16):2100-2111. doi: 10.1111/jocn.16101. Epub 2021 Nov 1.
2
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society.绝经后女性骨质疏松症的管理:北美更年期协会2021年立场声明
Menopause. 2021 Sep 1;28(9):973-997. doi: 10.1097/GME.0000000000001831.
3
Long-Term Treatment of Postmenopausal Osteoporosis.
撤回:补肾壮骨片联合常规方案对绝经后骨质疏松症患者骨密度改善、功能恢复及骨折风险预防作用的研究。
Comput Math Methods Med. 2023 Dec 6;2023:9783851. doi: 10.1155/2023/9783851. eCollection 2023.
4
Mechanisms of action and synergetic formulas of plant-based natural compounds from traditional Chinese medicine for managing osteoporosis: a literature review.中药植物源天然化合物防治骨质疏松症的作用机制及协同配方:文献综述
Front Med (Lausanne). 2023 Aug 28;10:1235081. doi: 10.3389/fmed.2023.1235081. eCollection 2023.
绝经后骨质疏松症的长期治疗。
Endocrinol Metab (Seoul). 2021 Jun;36(3):544-552. doi: 10.3803/EnM.2021.301. Epub 2021 Jun 22.
4
Responsiveness of the SF-36 general health domain: observations from 14883 spine surgery procedures.SF-36 一般健康领域的反应性:来自 14883 例脊柱手术的观察结果。
Qual Life Res. 2022 Feb;31(2):589-596. doi: 10.1007/s11136-021-02913-2. Epub 2021 Jun 19.
5
Denosumab versus romosozumab for postmenopausal osteoporosis treatment.地舒单抗与罗莫佐单抗治疗绝经后骨质疏松症。
Sci Rep. 2021 Jun 3;11(1):11801. doi: 10.1038/s41598-021-91248-6.
6
Botanicals in Postmenopausal Osteoporosis.绝经后骨质疏松症中的植物药
Nutrients. 2021 May 11;13(5):1609. doi: 10.3390/nu13051609.
7
Postmenopausal Osteoporosis: Latest Guidelines.绝经后骨质疏松症:最新指南
Endocrinol Metab Clin North Am. 2021 Jun;50(2):167-178. doi: 10.1016/j.ecl.2021.03.009.
8
Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial.白藜芦醇常规补充剂可改善绝经后女性的骨密度:一项随机、安慰剂对照试验。
J Bone Miner Res. 2020 Nov;35(11):2121-2131. doi: 10.1002/jbmr.4115. Epub 2020 Jul 14.
9
Gut microbiota and metabolite alterations associated with reduced bone mineral density or bone metabolic indexes in postmenopausal osteoporosis.与绝经后骨质疏松症患者骨密度或骨代谢指标降低相关的肠道微生物群和代谢物改变。
Aging (Albany NY). 2020 May 11;12(9):8583-8604. doi: 10.18632/aging.103168.
10
Improvement of body composition and bone mineral density after enteral nutrition in pediatric Crohn disease.肠内营养对小儿克罗恩病患者体成分和骨密度的改善作用。
Dig Liver Dis. 2020 Jun;52(6):630-636. doi: 10.1016/j.dld.2020.03.004. Epub 2020 Apr 6.